WeVote
Log In

Bill

Bill

H 4425

An Act relative to Medicare coverage of end-stage renal disease

194th Legislature (2025-2026) Introduced by Hannah Bowen and 3 co-sponsors

Massachusetts bill expanding Medicare coverage for end-stage renal disease treatment to improve patient access and reduce financial barriers to dialysis and transplant care.

Reporting date extended to Friday, July 31, 2026
0
WeVote Research Nonpartisan
Bill Summary · H 4425

Legislative bill overview

H 4425 seeks to expand Medicare coverage for end-stage renal disease (ESRD) treatment in Massachusetts. The bill addresses gaps in federal Medicare coverage by establishing state-level protections or supplementary benefits for ESRD patients. This appears to target dialysis, transplant support, or related therapies currently not fully covered under standard Medicare.

Why is this important

ESRD affects approximately 37,000 Massachusetts residents and represents one of the most expensive chronic conditions to treat. Inadequate coverage creates financial barriers to treatment, forces patients to delay care, and shifts costs to state Medicaid programs. Improved access directly impacts survival rates, quality of life, and overall state healthcare spending.

Potential points of contention

  • Federal-state jurisdiction: Medicare is federally administered; Massachusetts may face legal or procedural challenges implementing state-level coverage mandates
  • Cost implications: Expanded coverage requires funding; fiscal impact could affect state budget, Medicaid solvency, or require insurance premium increases
  • Coverage scope ambiguity: The bill's specific coverage additions are unclear from available records—dialysis frequency, home dialysis support, immunosuppressant drugs, or transplant medications have different cost-benefit profiles and may generate debate among providers and payers

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.